Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preetesh Jain, Hun Ju Lee, Jason Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair, Swami P. Iyer, Rashmi Kanagal-Shamanna, Ahmed Fetooh, Holly A Hill, Chi Young Ok, Wendy Chen, Onyeka Oriabure, Lei Feng, Guilin Tang, Francisco Vega, Maria Badillo, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2023-181312

Published: 2023

Journal Articles

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Vishakha Anand Pawar, Akanksha Aradhya, Daniel Galvan, Gautam Borthakur, Swami P. Iyer, Mark Kirschbaum, David Blake, Tapan M. Kadia, Deepa Sampath, Francisco Vega

Blood (2023) 142 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2023-178256

Published: 2023

Journal Articles

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 856.

https://doi.org/10.1182/blood-2023-180381

Published: 2023

Journal Articles

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Blood (2023) 142 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2023-191096

Published: 2023

Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2023-172537

Published: 2023

Journal Articles

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2023-187903

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

Alexandra Elias, Mario L. Marques-Piubelli, Ranjit Nair, Rishab Prakash, Sairah Ahmed, Luis Malpica, Hun Ju Lee, Jie Xu, Christopher R. Flowers, Sattva S. Neelapu, Francisco Vega, Roberto Miranda, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2023-187939

Published: 2023

Journal Articles

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Jason Westin, Ranjit Nair, Luis Fayad, Swami P. Iyer, Luis Malpica, Sattva S. Neelapu, Felipe Samaniego, Raphael Eric Steiner, Paolo Strati, Shivon Mathew, Donna Griffith, Loretta J. Nastoupil, Wirt Montinez, Maria Alma Rodriguez, Frederick Hagemeister, Lei Feng, Francisco Vega, Christopher R. Flowers, Sairah Ahmed

Blood (2023) 142 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2023-191123

Published: 2023

Journal Articles

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Abhishek Maiti, Naval Daver, Swami P. Iyer, David McCall, Satyen H Gohil, Javier Lopez Jimenez, Hayley Lane, Benjamin Kim, Kim-Hien Dao, Gary Patou, Sandip Panicker, Kelly Covert, Graham Carl Parry, Carl E Allen

Blood (2023) 142 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2023-177795

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference

Chen Zhou, Jie Xu, Rishab Prakash, Carlos P Torres-Cabala, Cheng-bang Chen, Kamesh Madduri, Arvind Rao, Greeshma Agasthya, Francisco Vega, Dennis O'Malley, L. Jeffrey Medeiros, Soundar Kumara, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 904.

https://doi.org/10.1182/blood-2023-187291

Published: 2023

Journal Articles

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Blood (2023) 142 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2023-181216

Published: 2023

Journal Articles

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Blood (2023) 142 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2023-187946

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Ugochi Ebinama, Rishab Prakash, Paolo Strati, Sairah Ahmed, Sherry Adkins, Samer A. Srour, Michael L. Wang, Preetesh Jain, Elizabeth J. Shpall, Anath Lionel, Meng Lui, Sattva S. Neelapu, Krina K. Patel, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2023-185190

Published: 2023

Journal Articles

Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3741–3743.

https://doi.org/10.1182/blood-2022-168540

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models

Daniela Y Santiesteban, Aundrietta D Duncan, Nadeem Q Mirza, Vincent Jacques, Sheila DeWitt, Swami P. Iyer

Blood (2022) 140 (Supplement 1): 8865–8866.

https://doi.org/10.1182/blood-2022-167495

Published: 2022

Journal Articles

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

Blood (2021) 138 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2021-148868

Published: 2021

NARROW

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only